Brazil’s health agency highlights drug substitutability in Bayer-União Química review
The Brazilian Health Regulatory Agency informed the Brazilian competition authority that while some drugs involved in União Química's acquisition of Bayer's portfolio have similar therapeutic purposes in hormonal replacement therapy, their...To view the full article, register now.
Already a subscriber? Click here to view full article